EVMN insider trading
HealthcareEvommune, Inc.: insider trade history from SEC Form 4 filings.
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
Company website: www.evommune.com
EVMN insider activity at a glance
FilingIQ tracks 50 insider transactions for EVMN in filings since Nov 12, 2025. The most recent transaction is dated Sep 30, 2026.
Across the full history, 7 open-market purchases
and 9 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest EVMN Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for EVMN?
- FilingIQ tracks 50 Form 4 insider transactions for EVMN (Evommune, Inc.), covering filings from Nov 12, 2025 onwards. 1 of those are dated within the last 90 days.
- Are EVMN insiders net buyers or net sellers?
- Across the full Form 4 history for EVMN, 7 transactions (14%) were open-market purchases and 9 (18%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does EVMN insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is EVMN in?
- Evommune, Inc. (EVMN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $983.55M.
Methodology & sources
Every EVMN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.